Relying On Human Factors Clinical Data For Regulatory Approvals

Why It Matters

Embedding robust human‑factors data early reduces the risk of regulatory delays and ensures devices perform safely in real‑world settings, directly impacting market approval timelines and patient outcomes.

Key Takeaways

• FDA increasing scrutiny on human factors in device approvals
• Human factors data must be integrated throughout product development lifecycle
• Missing early human factors often leads to complete response letters
• Clinical data alone can't prove effectiveness in real-world settings
• Regulators focus on human factors primarily during marketing application review

Summary

The discussion centered on the growing regulatory focus on human‑factors engineering in medical‑device submissions, especially within the FDA’s Center for Devices and Radiological Health. Participants noted that the agency’s human‑factors experts have become more visible over the past decade, and recent Complete Response Letters (CRLs) have explicitly cited deficiencies in usability data.

Key insights highlighted that while the FDA does not require extensive human‑factors evidence during early‑stage clinical trials, the lack of such data can trigger costly setbacks when a marketing application is reviewed. Companies that treat usability as an afterthought risk receiving CRLs that demand additional studies, effectively turning human factors into a bridge between controlled clinical outcomes and real‑world performance.

A memorable quote from the panelist emphasized, “Human factors is a bit of a bridge to clinical data… we need to know it works in people’s homes with or without training.” The example of a recent CRL that cited human‑factors shortcomings underscored how regulatory reviewers are now scrutinizing the practical deployment of devices, not just their technical specifications.

The implication for industry is clear: embed human‑factors testing early, document usability across intended environments, and align it with clinical efficacy data. Failure to do so can delay market entry, increase development costs, and jeopardize competitive positioning in a tightly regulated landscape.

Original Description

In this segment of the Drug Delivery Leader Live online event, Injected, Infused, or Implanted: A Penetrating Look At Patient Centricity, Chief Editor Tom von Gunden relays an audience question about increased FDA regulatory scrutiny around human factors. Panelists Jonathan Amaya-Hodes and Shannon Hoste comment on the importance of clinical data in regulatory submissions and in approval pathways.

See more at https://www.drugdeliveryleader.com/